Agendia BV, a Dutch maker of a breast cancer test with its U.S. headquarters and a lab in Huntington Beach, has raised $23 million in a fifth round of funding.
An undisclosed family investment firm provided half of the financing with investments from two undisclosed entrepreneurs and Agendia’s existing investors.
ING Groep NV and Dutch venture capital firms previously invested in Agendia, including a $34 million round in 2007.
Agendia makes a test designed to predict the reoccurrence of breast cancer in women who’ve been treated for the disease.
The funding was driven by increased use of Agendia’s MammaPrint test in the U.S., Chief Executive Bernhard Sixt said.
The Food and Drug Administration approved MammaPrint in 2007.
In May, Agendia opened a lab in Huntington Beach to run tests based on MammaPrint.
Agendia has 32 workers in Orange County.
The company was started in 2003 and also makes a test for drug makers.
